Abstract: An in-vehicle battery system comprises: a battery; a relay for establishing or cutting off an electrical connection between the battery and an inverter; a plurality of switches respectively provided in a current path for switching the relay; and a battery control apparatus that supervises a status of the battery. The plurality of switches include a first switch provided in the battery control apparatus and a second switch provided in a vehicle control apparatus which controls traveling of the vehicle; the first switch and the second switch are serially connected to each other in the current path; the battery control apparatus controls a status of switching the first switch; and the vehicle control apparatus controls a status of switching the second switch.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Abstract: A semiconductor substrate manufacturing method includes the steps of: forming, on a first surface of a first substrate, a plurality of terrace portions arranged in a first direction parallel to a horizontal plane of the first substrate, and a step portion having a predetermined height between two adjacent terrace portions in the first direction; forming a first semiconductor layer such that a part of the step portion is exposed; and vaporizing a portion of Si of the first substrate from a part of the step portion exposed from the first semiconductor layer by performing heat treatment on the first substrate on which the first semiconductor layer is formed, thereby forming a buffer layer having at least one graphene layer in at least a part between the first semiconductor layer and the first substrate.

Abstract: A surface-protective PSA sheet capable of reducing adherend damage and well maintaining appearance, etc is provided. The surface-protective PSA sheet capable of reducing adherend damage and well maintaining appearance, etc., comprises a surface layer, a resin substrate layer and a PSA layer, and has a multilayer structure with the resin substrate layer placed between the surface layer and the PSA layer, wherein the surface layer is a layer obtainable by curing a heat-curable composition comprising the following components: (a) a hydroxyl group-containing (meth)acrylic copolymer having a glass transition temperature of ?40° C. to 30° C.; (b) an allophanate polyisocyanate and/or a biuret polyisocyanate; and (c) a polysiloxane comprising a hydroxyl group-containing hydrocarbon group and/or polymer.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Abstract: Provided is a tobacco sheet for a non-combustion heating flavor inhaler, the tobacco sheet including a fibrous material.

Abstract: A material for a flavor inhalation article, said material being obtained by mixing a cellulosic base material and nicotine.

Abstract: A vehicle-side connector 1 includes a plurality of vehicle-side terminals 50, a connector housing 10 for holding the vehicle-side terminals 50 and heat storage materials 60 accommodated in the connector housing 10.

Abstract: This tobacco sheet for a non-combustion heating-type flavor inhaler contains a tobacco powder having a cumulative 90% particle diameter (D90) of at least 200 ?m in a volume-based particle size distribution as measured by a dry laser diffraction method.

Abstract: Provided is a tobacco sheet for a non-combustion-heating-type flavor inhaler, the tobacco sheet including a fibrous material.

Abstract: Provided is a tobacco sheet for a non-combustion heating flavor inhaler, the tobacco sheet including a fibrous material.

Abstract: This tobacco sheet for a non-combustion heating-type flavor inhaler contains a tobacco powder having a cumulative 90% particle diameter (D90) of at least 200 ?m in a volume-based particle size distribution as measured by a dry laser diffraction method.

Abstract: A flush water tank apparatus has a reservoir tank, a discharge valve, a discharge valve hydraulic drive portion configured to drive the discharge valve, and a discharge/vacuum break valve device configured to supply the water supplied from the upstream side to the discharge valve hydraulic drive portion on a downstream side. The discharge valve hydraulic drive portion includes a cylinder, and a piston configured to be moved by a pressure of the water flowing into the cylinder to move the discharge valve. The discharge/vacuum break valve device includes a valve body that operates to discharge the water flowing backward from the discharge valve hydraulic drive portion while opening the upstream side to an atmosphere when the supply of the water from the upstream side is stopped.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.